Search

Your search keyword '"Raimondo, F."' showing total 1,744 results
Start Over Author "Raimondo, F."
1,744 results on '"Raimondo, F."'

1. Multimodal assessment improves neuroprognosis performance in clinically unresponsive critical-care patients with brain injury

Author

Rohaut, B., Calligaris, C., Hermann, B., Perez, P., Faugeras, F., Raimondo, F., King, J-.R., Engemann, D., Marois, C., Le Guennec, L., Di Meglio, L., Sangaré, A., Munoz Musat, E., Valente, M., Ben Salah, A., Demertzi, A., Belloli, L., Manasova, D., Jodaitis, L., Habert, M. O., Lambrecq, V., Pyatigorskaya, N., Galanaud, D., Puybasset, L., Weiss, N., Demeret, S., Lejeune, F. X., Sitt, J. D., and Naccache, L.

Published
2024
Full Text
View/download PDF

2. MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes

Author

Giallongo, C., Dulcamare, I., Giallongo, S., Duminuco, A., Pieragostino, D., Cufaro, M. C., Amorini, A. M., Lazzarino, G., Romano, A., Parrinello, N., Di Rosa, M., Broggi, G., Caltabiano, R., Caraglia, M., Scrima, M., Pasquale, L. S., Tathode, M. S., Li Volti, G., Motterlini, R., Di Raimondo, F., Tibullo, D., and Palumbo, G. A.

Published
2023
Full Text
View/download PDF

4. Linking brain structure and genetic risk in large-scale data: A comparison of shared versus predominantly disorder-specific genetic risk for neuropsychiatric disorders

Author

Federmann, L., primary, Sindermann, L., additional, Primus, S., additional, Raimondo, F., additional, Oexle, K., additional, Goltermann, J., additional, Winkelmann, J., additional, Nöthen, M.M., additional, Amunts, K., additional, Mühleisen, T.W., additional, Cichon, S., additional, Eickhoff, S.B., additional, Hoffstaedter, F., additional, Dannlowski, U., additional, Patil, K.R., additional, and Forstner, A.J., additional

Published
2024
Full Text
View/download PDF

5. Vacuolar Proton-Translocating ATPase May Take Part in the Drug Resistance Phenotype of Glioma Stem Cells

Author

Giambra, M, Di Cristofori, A, Raimondo, F, Rigolio, R, Conconi, D, Chiarello, G, Tabano, S, Antolini, L, Nicolini, G, Bua, M, Ferlito, D, Carrabba, G, Giussani, C, Lavitrano, M, Bentivegna, A, Giambra, Martina, Di Cristofori, Andrea, Raimondo, Francesca, Rigolio, Roberta, Conconi, Donatella, Chiarello, Gaia, Tabano, Silvia Maria, Antolini, Laura, Nicolini, Gabriella, Bua, Miriam, Ferlito, Davide, Carrabba, Giorgio, Giussani, Carlo Giorgio, Lavitrano, Marialuisa, Bentivegna, Angela, Giambra, M, Di Cristofori, A, Raimondo, F, Rigolio, R, Conconi, D, Chiarello, G, Tabano, S, Antolini, L, Nicolini, G, Bua, M, Ferlito, D, Carrabba, G, Giussani, C, Lavitrano, M, Bentivegna, A, Giambra, Martina, Di Cristofori, Andrea, Raimondo, Francesca, Rigolio, Roberta, Conconi, Donatella, Chiarello, Gaia, Tabano, Silvia Maria, Antolini, Laura, Nicolini, Gabriella, Bua, Miriam, Ferlito, Davide, Carrabba, Giorgio, Giussani, Carlo Giorgio, Lavitrano, Marialuisa, and Bentivegna, Angela

Abstract

The vacuolar proton-translocating ATPase (V-ATPase) is a transmembrane multi-protein complex fundamental in maintaining a normal intracellular pH. In the tumoral contest, its role is crucial since the metabolism underlying carcinogenesis is mainly based on anaerobic glycolytic reactions. Moreover, neoplastic cells use the V-ATPase to extrude chemotherapy drugs into the extra-cellular compartment as a drug resistance mechanism. In glioblastoma (GBM), the most malignant and incurable primary brain tumor, the expression of this pump is upregulated, making it a new possible therapeutic target. In this work, the bafilomycin A1-induced inhibition of V-ATPase in patient-derived glioma stem cell (GSC) lines was evaluated together with temozolomide, the first-line therapy against GBM. In contrast with previous published data, the proposed treatment did not overcome resistance to the standard therapy. In addition, our data showed that nanomolar dosages of bafilomycin A1 led to the blockage of the autophagy process and cellular necrosis, making the drug unusable in models which are more complex. Nevertheless, the increased expression of V-ATPase following bafilomycin A1 suggests a critical role of the proton pump in GBM stem components, encouraging the search for novel strategies to limit its activity in order to circumvent resistance to conventional therapy.

Published
2024

11. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)

Author

Iannitto, E., primary, Balzarotti, M., additional, Martelli, M., additional, Zinzani, P., additional, Tucci, A., additional, Di Rocco, A., additional, Cavallo, F., additional, Usai, S. V., additional, Guidetti, A., additional, Ravano, E., additional, Merli, F., additional, Botto, B., additional, Pelosini, M., additional, Tecchio, C., additional, Spina, M., additional, Derenzini, E., additional, Finotto, S., additional, Mola, B., additional, Pinto, A., additional, Zanni, E., additional, Battistini, R., additional, Hohaus, S., additional, Dogliotti, I., additional, Gini, G., additional, Zilioli, V. R., additional, De Lorenzo, S., additional, Dodero, A., additional, Broccoli, A., additional, Maggi, A., additional, Mannarella, C., additional, Chiarenza, A., additional, Pastore, D., additional, Cascavilla, N., additional, Musto, P., additional, Stelitano, C., additional, Di Raimondo, F., additional, Di Renzo, N., additional, Liberati, A. M., additional, Salerno, M., additional, Scalone, R., additional, Nassi, L., additional, Patti, C., additional, Polizzi, V., additional, Guarini, A., additional, Amato, G., additional, Ciccone, G., additional, Evangelista, A., additional, Lo Presti, F., additional, La Porta, A., additional, Mannina, D., additional, Calogero, R. D., additional, Musso, M., additional, and Consoli, U., additional

Published
2023
Full Text
View/download PDF

15. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., Rossi D., Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., and Rossi D.

Abstract

NA

Published
2023

16. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, R., Rossi, Federica Maria, Vit, F., Bittolo, T., Zucchetto, A., Papotti, R., Tissino, E., Pozzo, F., Degan, M., Polesel, J., Bulian, P., Marasca, R., Reda, G., Laurenti, Luca, Olivieri, J., Chiarenza, A., Laureana, R., Postorino, M., Del Principe, M. I., Cuneo, A., Gentile, M., Morabito, Francesco, Fronza, G., Tafuri, A., Zaja, F., Foa, Robin, Di Raimondo, F., Del Poeta, G., Gattei, V., Rossi F. M., Laurenti L. (ORCID:0000-0002-8327-1396), Morabito F., Foa R., Bomben, R., Rossi, Federica Maria, Vit, F., Bittolo, T., Zucchetto, A., Papotti, R., Tissino, E., Pozzo, F., Degan, M., Polesel, J., Bulian, P., Marasca, R., Reda, G., Laurenti, Luca, Olivieri, J., Chiarenza, A., Laureana, R., Postorino, M., Del Principe, M. I., Cuneo, A., Gentile, M., Morabito, Francesco, Fronza, G., Tafuri, A., Zaja, F., Foa, Robin, Di Raimondo, F., Del Poeta, G., Gattei, V., Rossi F. M., Laurenti L. (ORCID:0000-0002-8327-1396), Morabito F., and Foa R.

Abstract

NA

Published
2023

18. P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS

Author

Barilà, G., primary, Pascarella, A., additional, Conticello, C., additional, Mina, R., additional, Marcon, C., additional, Fazio, F., additional, Cartia, C., additional, Buda, G., additional, Pilerci, S., additional, Rocchi, S., additional, Maroccia, A., additional, Sgherza, N., additional, Porrazzo, M., additional, Pescosta, N., additional, Furlan, A., additional, Scomazzon, E., additional, Mele, G., additional, Gentile, M., additional, Del Giudice, M.L., additional, Schininà, G., additional, Pavan, L., additional, De Cicco, G., additional, Casson, A., additional, Lisi, C., additional, Antonioli, E., additional, Mangiacavalli, S., additional, Musto, P., additional, Gay, F., additional, Zamagni, E., additional, Petrucci, M.T., additional, Di Raimondo, F., additional, Patriarca, F., additional, Bassan, R., additional, and Zambello, R., additional

Published
2023
Full Text
View/download PDF

19. P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

Author

Offidani, M., primary, Morè, S., additional, Cavo, M., additional, Derudas, D., additional, Di Raimondo, F., additional, Cuneo, A., additional, Baldini, L., additional, Della Pepa, R., additional, Musso, M., additional, Boccadoro, M., additional, Musto, P., additional, Belotti, A., additional, Fioritoni, F., additional, Di Renzo, N., additional, Mele, A., additional, Gamberi, B., additional, De Paoli, L., additional, Zambello, R., additional, Grammatico, S., additional, Brociner, M., additional, Fazio, F., additional, and Petrucci, M. T., additional

Published
2023
Full Text
View/download PDF

20. P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA

Author

Giallongo, C., primary, Zuppelli, T., additional, Scandura, G., additional, La Spina, E., additional, Dulcamare, I., additional, Cambria, D., additional, Giallongo, S., additional, Romano, A., additional, Parrinello, N., additional, Del Fabro, V., additional, Aguennoz, M., additional, Li Volti, G., additional, Palumbo, G.A., additional, Di Raimondo, F., additional, and Tibullo, D., additional

Published
2023
Full Text
View/download PDF

21. MACROH2A1.1 SITS AT THE INTERPLAY BETWEEN EPIGENETICS AND INFLAMMATION OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES

Author

Giallongo, C., primary, Dulcamare, I., additional, Giallongo, S., additional, Duminuco, A., additional, Pieragostino, D., additional, Cufaro, M.C., additional, Amorini, A.M., additional, Lazzarino, G., additional, Romano, A., additional, Parrinello, N., additional, Marino, S., additional, Di Rosa, M., additional, Broggi, G., additional, Caltabiano, R., additional, Li Volti, G., additional, Motterlini, R., additional, Di Raimondo, F., additional, Tibullo, D., additional, and Palumbo, G., additional

Published
2023
Full Text
View/download PDF

22. P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS

Author

Romano, A., primary, Scandura, G., additional, Giallongo, C., additional, La Spina, E., additional, Giallongo, S., additional, Longhitano, L., additional, Zuppelli, T., additional, Dulcamare, I., additional, Parrinello, N. L., additional, Polito, F., additional, Oteri, R., additional, Aguennouz, M., additional, Vicario, N., additional, Amorini, A. M., additional, Del Fabro, V., additional, Conticello, C., additional, Li Volti, G., additional, Palumbo, G. A., additional, Tibullo, D., additional, and Di Raimondo, F., additional

Published
2023
Full Text
View/download PDF

23. P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA

Author

Duminuco, A., primary, Romano, A., additional, Leotta, D., additional, La Spina, E., additional, Cambria, D., additional, Bulla, A., additional, Del Fabro, V., additional, Tibullo, D., additional, Giallongo, C., additional, Palumbo, G.A., additional, Conticello, C., additional, and Di Raimondo, F., additional

Published
2023
Full Text
View/download PDF

27. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Author

Hoffmann, V S, Baccarani, M, Hasford, J, Castagnetti, F, Di Raimondo, F, Casado, L F, Turkina, A, Zackova, D, Ossenkoppele, G, Zaritskey, A, Höglund, M, Simonsson, B, Indrak, K, Sninska, Z, Sacha, T, Clark, R, Bogdanovic, A, Hellmann, A, Griskevicius, L, Schubert-Fritschle, G, Sertic, D, Guilhot, J, Lejniece, S, Zupan, I, Burgstaller, S, Koskenvesa, P, Everaus, H, Costeas, P, Lindoerfer, D, Rosti, G, Saussele, S, Hochhaus, A, and Hehlmann, R

Published
2017
Full Text
View/download PDF

28. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

31. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

Author

Gentile, M, Shanafelt, T D, Cutrona, G, Molica, S, Tripepi, G, Alvarez, I, Mauro, F R, Di Renzo, N, Di Raimondo, F, Vincelli, I, Todoerti, K, Matis, S, Musolino, C, Fabris, S, Vigna, E, Levato, L, Zupo, S, Angrilli, F, Consoli, U, Festini, G, Longo, G, Cortelezzi, A, Arcari, A, Federico, M, Mannina, D, Recchia, A G, Neri, A, Kay, N E, Ferrarini, M, and Morabito, F

Published
2016
Full Text
View/download PDF

32. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., Del Poeta G., Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., and Del Poeta G.

Abstract

Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect drug management. We confirmed the role of CIRS . 6 as a predictor of a poorer progression- and event-free survival (PFS, EFS). The presence of a severe comorbidity was significantly associated with permanent dose reductions (PDRs), not translating into worse outcomes. As expected, del(17p) and/or TP53mut and previous therapies affected PFS, EFS, and overall survival. No study so far has analyzed the influence of concomitant medications and CYP3A inhibitors with ibrutinib. In our series, these factors had no impact, although CYP3A4 inhibitors use correlated with Cox regression analysis, with an increased risk of PDR. Despite the limitation of its retrospective nature, this large study confirmed the role of ECOG-PS as the most accurate predictor of ibrutinib feasibility and outcomes, and importantly, neutropenia emerged as a relevant tool influencing patients’ vulnerability. Although CIRS > 6 retained a significant impact on PFS and EFS, its value should be confirmed by prospective studies.

Published
2021

33. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Author

Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foa R, Chiaretti, S, Messina, M, Della Starza, I, Piciocchi, A, Cafforio, L, Cavalli, M, Taherinasab, A, Ansuinelli, M, Elia, L, Petroni, G, La Starza, R, Canichella, M, Lauretti, A, Puzzolo, M, Pierini, V, Santoro, A, Spinelli, O, Apicella, V, Capria, S, Di Raimondo, F, De Fabritiis, P, Papayannidis, C, Candoni, A, Cairoli, R, Cerrano, M, Fracchiolla, N, Mattei, D, Cattaneo, C, Vitale, A, Crea, E, Fazi, P, Mecucci, C, Rambaldi, A, Guarini, A, Bassan, R, Foa, R, Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Petroni GA, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, and Foa R

Abstract

Early recognition of Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) cases could impact on the management and outcome of this subset of B-lineage ALL. In order to assess the prognostic value of the Ph-like status in a pediatric-inspired, minimal residual disease (MRD)driven trial, we screened 88 B-lineage ALL cases negative for major fusion genes (BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 and KTM2Ar) enrolled in the GIMEMA LAL1913 front-line protocol for adult BCR/ABL1-negative ALL. The screening - performed using the “BCR/ABL1-like predictor” - identified 28 Ph-like cases (31.8%), characterized by CRLF2 overexpression (35.7%), JAK/STAT pathway mutations (33.3%), IKZF1 (63.6%), BTG1 (50%) and EBF1 (27.3%) deletions, and rearrangements targeting tyrosine kinases or CRLF2 (40%). The correlation with outcome highlighted that: i) the complete remission rate was significantly lower in Ph-like compared to non-Ph-like cases (74.1% vs. 91.5%, P=0.044); ii) at time point 2, decisional for transplant allocation, 52.9% of Ph-like cases versus 20% of non-Ph-like were MRD-positive (P=0.025); iii) the Ph-like profile was the only parameter associated with a higher risk of being MRD-positive at time point 2 (P=0.014); iv) at 24 months, Ph-like patients had a significantly inferior event-free and disease-free survival compared to non-Ph-like patients (33.5% vs. 66.2%, P=0.005 and 45.5% vs. 72.3%, P=0.062, respectively). This study documents that Ph-like patients have a lower complete remission rate, event-free survival and disease-free survival, as well as a greater MRD persistence also in a pediatric-oriented and MRD-driven adult ALL protocol, thus reinforcing that the early recognition of Ph-like ALL patients at diagnosis is crucial to refine risk-stratification and to optimize therapeutic strategies.

Published
2021

40. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Author

Hoffmann, V S, Baccarani, M, Hasford, J, Lindoerfer, D, Burgstaller, S, Sertic, D, Costeas, P, Mayer, J, Indrak, K, Everaus, H, Koskenvesa, P, Guilhot, J, Schubert-Fritschle, G, Castagnetti, F, Di Raimondo, F, Lejniece, S, Griskevicius, L, Thielen, N, Sacha, T, Hellmann, A, Turkina, A G, Zaritskey, A, Bogdanovic, A, Sninska, Z, Zupan, I, Steegmann, J-L, Simonsson, B, Clark, R E, Covelli, A, Guidi, G, and Hehlmann, R

Published
2015
Full Text
View/download PDF

43. P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).

Author

Garibaldi, B., primary, Franciosa, M., additional, Pilo, F., additional, Menotti, D., additional, Cardinali, V., additional, Brunetti, L., additional, Martino, E. A., additional, Vigna, E., additional, Tanasi, I., additional, Duminuco, A., additional, Maugeri, C., additional, Parisi, M. S., additional, Fiumara, P. F., additional, Mauro, E., additional, Gentile, M., additional, Martelli, M. P., additional, Capelli, D., additional, Romani, C., additional, Galimberti, S., additional, Palumbo, G. A., additional, Di Raimondo, F., additional, and Vetro, C., additional

Published
2022
Full Text
View/download PDF

44. S136: CONSTITUTIVE VLA-4 ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE OTHER SIDE OF BCR AUTONOMOUS SIGNALING.

Author

Tissino, E., primary, Bomben, R., additional, Maity, P. C., additional, Pozzo, F., additional, Forestieri, G., additional, Nicolò, A., additional, Härzschel, A., additional, Bittolo, T., additional, Rossi, F. M., additional, Datta, M., additional, Zaja, F., additional, Capasso, G., additional, D’Arena, G., additional, Chiarenza, A., additional, Di Raimondo, F., additional, Jumaa, H., additional, Rossi, D., additional, Del Poeta, G., additional, Hartmann, T. N., additional, Zucchetto, A., additional, and Gattei, V., additional

Published
2022
Full Text
View/download PDF

45. PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION

Author

Romano, A., primary, Conticello, C., additional, Filetti, S., additional, Bulla, A., additional, Chiarenza, A., additional, Del Fabro, V., additional, Leotta, S., additional, Markovic, U., additional, Motta, G., additional, Parisi, M., additional, Stagno, F., additional, Palumbo, G. A., additional, and Di Raimondo, F., additional

Published
2022
Full Text
View/download PDF

46. P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS

Author

Oliva, E. N., primary, Salutari, P., additional, Di Raimondo, F., additional, Reda, G., additional, Capelli, D., additional, Iannì, G., additional, Tripepi, G., additional, Alati, C., additional, Mammì, C., additional, D’Errigo, M. G., additional, Niscola, P., additional, Selleri, C., additional, Musto, P., additional, Vigna, E., additional, Volpe, A., additional, Cascavilla, N., additional, Cannatà, M. C., additional, Mannina, D., additional, and Candoni, A., additional

Published
2022
Full Text
View/download PDF

47. P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

Author

Giuffrida, G., primary, Markovic, U., additional, Conticello, C., additional, Nicolosi, D., additional, Calafiore, V., additional, Romano, A., additional, Condorelli, A., additional, Grasso, S., additional, Duminuco, A., additional, Calagna, M., additional, Nardo, A., additional, Riccobene, C., additional, Esposito, B., additional, Consoli, U., additional, Di Giacomo, V., additional, Neri, S., additional, Cingari, M. R., additional, Iaria, G., additional, Innao, V., additional, Spina, M., additional, Gentile, J., additional, Zizzo, C., additional, Duro, G., additional, and Di Raimondo, F., additional

Published
2022
Full Text
View/download PDF

48. P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE

Author

Bomben, R., primary, Rossi, F. M., additional, Vit, F., additional, Bittolo, T., additional, Zucchetto, A., additional, Papotti, R., additional, Tissino, E., additional, Pozzo, F., additional, Degan, M., additional, Zaina, E., additional, Cattarossi, I., additional, Nanni, P., additional, Marasca, R., additional, Reda, G., additional, Laurenti, L., additional, Olivieri, J., additional, Chiarenza, A., additional, Ballotta, L., additional, Cuneo, A., additional, Gentile, M., additional, Morabito, F., additional, Tafuri, A., additional, Zaja, F., additional, Foà, R., additional, Di Raimondo, F., additional, Del Poeta, G., additional, and Gattei, V., additional

Published
2022
Full Text
View/download PDF

49. P731: INTERPLAY BETWEEN INFLAMMATION AND EPIGENETICS IN TUMOR REPROGRAMMING OF MESENCHYMAL STROMAL CELLS (MSCS) IN MYELODYSPLASTIC SYNDROMES (MDS)

Author

Giallongo, C., primary, Dulcamare, I., additional, Tibullo, D., additional, Pieragostino, D., additional, Cufaro, M. C., additional, Amorini, M. A., additional, Lazzarino, G., additional, Romano, A., additional, Scandura, G., additional, Zuppelli, T., additional, Di Rosa, M., additional, Duminuco, A., additional, Broggi, G., additional, Caltabiano, R., additional, Floresti, R., additional, Motterlini, R., additional, Di Raimondo, F., additional, and Palumbo, G. A., additional

Published
2022
Full Text
View/download PDF

50. P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS

Author

Martino, E. A., primary, Conticello, C., additional, Zamagni, E., additional, Pavone, V., additional, Palmieri, S., additional, Musso, M., additional, Tacchetti, P., additional, Mele, A., additional, Catlano, L., additional, Vigna, E., additional, Bruzzese, A., additional, Mendicino, F., additional, Botta, C., additional, Vincelli, D., additional, Farina, G., additional, Barone, M., additional, Cangialosi, C., additional, Mancuso, K., additional, Rizziello, I., additional, Rocchi, S., additional, Falcone, A. P., additional, Mele, G., additional, Reddiconto, G., additional, Garibaldi, B., additional, Iaccino, E., additional, Tripepi, G., additional, Di Raimondo, F., additional, Musto, P., additional, Neri, A., additional, Cavo, M., additional, Morabito, F., additional, and Gentile, M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results